Compare DexCom, Inc. (DXCM) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.08B), while Vanguard Total International Stock Index Fund ETF trades at $87. Which is the better fit depends on your goals.
| DXCM | VXUS | |
|---|---|---|
Market Cap | $33.08B | — |
Sector | Health | Sector/Thematic |
52-Week High | $89.53 | $87.21 |
52-Week Low | $54.84 | $70.87 |
Enterprise Value | $32.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
VXUS trades at $87.21, up 1.03% with strong bullish technical signals from moving averages. The ETF offers broad international diversification with over 8,700 non-U.S. stocks, recently delivering 27.82% total returns over the past year according to Seeking Alpha (August 8, 2026). Institutional interest is growing with multiple firms increasing positions, while analysts highlight its valuation discount to U.S. equities.
The outlook remains positive given international diversification benefits and institutional accumulation, though RSI levels suggest potential near-term consolidation. Key risks include global economic volatility and currency fluctuations. Wall Street sentiment leans bullish with Seeking Alpha maintaining a Buy rating, supported by the ETF's low expense ratio and comprehensive market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
